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A year ago the World Stroke Organisation (WSO) highlighted the enormous global 
impact of the COVID-19 pandemic on stroke care. In this review we consider a year 
later where we are now, what the future holds, and what the long term effects of the 
pandemic will be on stroke. Stroke occurs in about 1.4% of patients hospitalised with 
COVID-19 infection, who show an excess of large vessel occlusion and increased 
mortality. Despite this association, stroke presentations fell dramatically during the 
pandemic, although emerging data suggests that total stroke mortality may have risen 
with increased stroke deaths at home and in care homes. Strategies and guidelines 
have been developed to adapt stroke services worldwide, and protect healthcare 
workers. Adaptations include increasing use of telemedicine for all aspects of stroke 
care. The pandemic is exacerbating already marked global inequalities in stroke 
incidence and mortality. Lastly the pandemic has had a major impact on stroke 
research and funding, although it has also emphasised the importnace of large scale 








It is a year since the World Stroke Organisation (WSO) highlighted the enormous 
global impact of the COVID-19 pandemic on stroke care. Not only was there the 
worrying concern that COVID-19 infection itself may increase stroke risk, but a WSO 
survey highlighted the impact of the pandemic on stroke care with delayed 
presentation and reduced hospital admission, and less availability of specialised 
stroke services due to diversion of resources to the care of COVID-19 patients.(1) The 
last year has seen intense efforts to better understand the relationship between 
COVID-19 and stroke, to adapt stroke services to ensure adequate stroke care despite 
the constraints of the pandemic, and to ensure safety of both health professionals and 
patients. It is timely to consider where we are now, what the future holds, and what the 
long-term effects on stroke will be.  
 
Does COVID-19 Cause Stroke? 
 
A recent systematic review and metanalysis of 108571 COVID-19 patients, in 1106 of 
whom ischaemic or haemorrhagic stroke occurred, yielded an overall pooled incidence 
of acute stroke in COVID-19 patients of 1.4% (95% CI 1.0-1.9).(2) What proportion of 
these strokes are causally related to COVID infection, and what proportion are 
incidentally related, is still uncertain. However increasing data suggests, that at least 
in a proportion, the two are causally related. Evidence supporting a causal relation 
comes from an epidemiological study that found COVID-19 is associated with a 7.6 
fold increased risk in the odds of stroke compared with influenza.(3) Furthermore a 
characteristic pattern of stroke is seen in many COVID-19 patients. Stroke patients 
with COVID-19 were younger and less likely to have hypertension and previous stroke, 
than stroke patients without COVID-19. Large artery occlusion is much more common 
in COVID-19 associated stroke, and a characteristic pattern with infarcts in multiple 
arterial territories was reported in 43% of cases.(2) The majority of strokes are 
ischaemic with only approximately 10% being haemorrhagic. The most common 
stroke mechanism was found to be cryptogenic in 45%, followed by cardioembolic in 
22%, large vessel atherosclerotic in 11% and small artery stroke in only 3%.(2) COVID 
associated with stroke was associated with a much higher mortality and increased 
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disability, although this may partly reflect the predominance of large artery strokes and 
the fact that stroke in COVID-19 patients was often associated with severe COVID-19 
infection.(2)  
 
How might COVID-19 increase stroke risk and does this have implications for therapy? 
 
Mechanisms underlying stroke in patients with COVID-19 are likely to be multifactorial. 
In some patients they could be related to conventional stroke mechanisms, with 
COVID-19 acting as a trigger, and this is consistent with conventional risk factors such 
as hypertension, diabetes mellitus and coronary artery disease being associated with 
increased stroke risk in individuals with COVID-19 infection.(2) However in others 
stroke may be directly caused by COVID-19 infection through specific 
pathophysiological mechanisms. Activation of the coagulation pathway, with elevated 
D-dimer and fibrinogen which have been reported in patients with COVID-19 and 
stroke, has been suggested as one mediating pathway. (2) This coagulopathy, related 
to the infection-induced systemic inflammatory response, may contribute to the risk of 
both stroke by casing both arterial thrombosis, and also venous thrombosis with 
paradoxical embolism. This may explain why large vessel occlusion is seen in some 
younger individuals who have no vascular risk factors. Anticardiolipin antibodies have 
also been reported in some patients with COVID-19, and may relate to increased 
thrombosis risk, although more data is required.(4) A characteristic feature of severe 
COVID-19 infection is the ‘cytokine storm’. This describes uncontrolled activation of 
the immune system caused by the viral infection with subsequent excessive cytokine 
release, which may itself result in thrombosis, as well as plaque rupture and 
endothelial injury. Direct myocardial injury has also been described including 
myocardial dysfunction related to the cytokine storm, and viral myocarditis, and these 
may lead to cardiac arrhythmias and intracardiac thrombus, possibly exacerbated by 
the hypercoagulable state, and therefore cardioembolic stroke.(5) 
 
Direct viral invasion has also been suggested as a disease mechanism. COVID-19 
uses the angiotensin-converting enzyme 2 (ACE-2) receptor to enter cells. This 
receptor is expressed in vascular endothelium as well as heart, lungs and kidneys and 
direct invasion of endothelial cells causing an ‘endotheliitis’ has been proposed as one 
mechanism contributing to the thrombotic complications of COVID-19.(2)  Although 
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acute lacunar stroke appears less common in COVID-19 infection radiological 
changes of cerebral small vessel disease including cerebral microbleeds have been 
reported.(6) It has been suggested these could result from both endothelial injury 
precipitated by the mechanisms above, and also hypoxemia.  
 
The increased risk of thrombosis, including venous thrombosis(7),  has led to the 
recommendation that all hospitalised patients with COVID-19 should receive 
prophylactic heparin(8).  It has been hypothesized that full dose anticoagulation may 
also reduce thrombosis in small arteries in multiple organs including the lungs, and 
therefore could reduce disease severity and the need for ventilatory support. Early 
trials suggested no benefit of full anticoagulation in COVID-19 patients on ventilators, 
but more recent data suggests a possible benefit in patients with less severe COVID 
in reducing progression of respiratory disease.(9) Whether such approaches will 
reduce the frequency of thrombotic events such as stroke remains to be determined. 
However such approaches are likely to have a limited effect on reducing stroke 
incidence associated with COVID because the majority of patients with stroke and 
COVID, present with the stroke itself rather than developing stroke while in hospital; 
84% in a recent systematic review. (2) 
 
The Impact of the Pandemic on Stroke Services 
 
Initial monitoring by the WSO revealed widespread effects of the pandemic on delivery 
of stroke services.(1) Most countries saw significant service reorganization, and WSO 
members reported reallocation of neurology and stroke beds including intensive care 
facilities to COVID-19 patients, necessitating a move of stroke units to less optimal 
accommodation, as well as redeployment of stroke physicians, nurses, and other 
stroke healthcare related workers to the care of COVID-19 patients. Since these early 
observations, numerous studies have documented these effects. A meta-analysis of 
9 studies in 59233 subjects reported a drop to 64% in the number of stroke alerts, a 
drop to 69% in reperfusion therapies,  and a drop in of mechanical thrombectomies to 
78%.(10) These effects appear to be global. A recent large collaborative study 
between the Society of Vascular and Interventional Neurology, the Middle East and 
North Africa Stroke and Interventional Neurotherapies Organisation, the Japanese 
Interventional Neurology Society, and academic partners from 6 continents and 40 
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countries reported a global decline in the volume of overall stroke hospitalisations, 
mechanical thrombectomy procedures, and intracranial haemorrhage admissions.(11) 
These reductions were observed regardless of COVID-19 hospitalisation burden and 
pre-stroke and mechanical thrombectomy volumes. Declines in stroke hospitalisations 
and MT volumes were if anything greater in mid and high volume versus low volume 
stroke centres, perhaps related to the fact that larger centres are more likely to become 
the preferred destination for COVID-19 referrals due to capacity issues.  
 
Reassuringly COVID-19 patients do seem to be receiving reperfusion therapies 
despite the challenges delivering them during the pandemic. In one meta-analysis the 
ratio of the number of mechanical thrombectomies to stroke patients was reported to 
be higher than usual with an odds ratio of 1.23, perhaps reflecting the increased 
incidence of large artery occlusion associated with COVID-19 infection. A more recent 
metanalysis including 18 cohorts studies involving 67 845 patients reported that 
COVID-19 infection was not associated with any alteration in the chance of receiving 
intravenous thrombolysis (OR 1.42, 95% CI 0.65-3.10) or thrombectomy (OR 0.78, 
95% CI 0.35-1.74).(12)  
 
The reasons for this reduction in activity have been debated. A major factor is likely to 
have been reduced presentation of patients with stroke, particularly with milder 
symptoms, due to concerns about the risk of catching COVID-19 infection in 
hospital.(13)  Physical distancing measures may also have prevented patients 
suffering from a stroke being witnessed at that time. Another alternative could be 
reduced hospital access for COVID-19 patients, although international studies have 
suggested this was unlikely to be the case. Whether the incidence of stroke itself has 
altered remains uncertain. It has been suggested that the environmental 
consequences of a lockdown, with improved patient behavior and medication 
compliance might reduce vascular events, while a reduction in exposure to other 
common viruses, or even reduced levels of pollution, might result in reduced triggering 
of vascular events including stroke risk. On the other hand COVID-19 appears to be 
causally related to stroke at least in some cases.(2) A recent population based study 
reported that despite this reduction in stroke presentations there was actually an 
increase in total stroke deaths, but that most of these occurred in the community at 
home and particularly in nursing homes, while in hospital stroke deaths fell.(14)  We 
Author Accepted Manuscript
await longer term population based studies to fully understand the true effect of the 
pandemic on stroke incidence.  
 
Adapting Stroke Services 
 
In response to the pressure on stroke services, numerous National and International 
guidelines have been developed both on the web and as publications. (15,16,17,18) 
Algorithms have been developed for optimal acute stroke care to ensure rapid 
diagnosis of COVID infection in stroke patients, protection of patients and healthcare 
staff, and optimal practices to maintain delivery of reperfusion services both 
thrombolysis and thrombectomy. The importance of telemedicine has been widely 
recognised. Tele-stroke networks were already implemented worldwide for delivery of 
thrombolysis, but these practices have been extended to help provide acute stroke 
care during the pandemic.(19)  Adaptions have been made to deliver stroke care in 
low resource setting, including those caused by the pandemic. For example, an 
emerging concern in low-resource environments is whether the monitoring intensity of 
a subpopulation of acute ischemic stroke (AIS) patients undergoing treatment with 
intravenous thrombolysis (IVT) can safely be reduced.  A low-intensity monitoring 
protocol for patients treated with thrombolysis in whom the NIH Stroke Scale (NIHSS) 
was less than 10 at the time of presentation  was successfully piloted (20) and is now 
being evaluated in the International OPTIMIST trial in 12000 participants (21)  A global 
campaign (#StrokeDontStayAtHome) was created by the WSO in collaboration with 
the Angels Initiative to raise awareness of the need for people to call an ambulance 




The pandemic has also challenged provision of outpatient stroke care and 
rehabilitation. Many TIA services have been switched to virtual with the use of either 
telephone or video telemedicine technology, often with surprisingly good results. 
Telemedicine approaches have also been suggested for some rehabilitation services; 
this does limit the range of rehabilitation that can be provided, although a recent 
randomised controlled trial showed encouraging results for delivery of home-based 
motor training telerehabilitation program on motor function in patients with stroke.(22) 
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Many patients have received less rehabilitation both due to earlier discharge both to 
free up hospital beds and avoid risk of in hospital infection, and reduced availability of 
community rehabilitation services. There have been concerns that this could have long 
term consequences on stroke outcome. Guidelines have been produced for the 
longer-term restoration and recovery of stroke services.(23) 
 
Does Stroke Increase the Risk of Severe COVID-19 Infection?  
 
An initial concern to our patients was the possibility that previous stroke could increase 
the severity of COVID-19 infection. An early metanalysis suggested there was a 2.5 
fold increase in the risk of severe COVID-19 in those with a history of cerebrovascular 
disease.(24) A similar odds ratio has been reported in more recent larger studies.(25) 
However much of this appears to be related to comorbidities. For example, a more 
recent study showed markedly higher risks of hospitalisation (32.4% versus 11.7%) 
and death (13.4% versus 3.6%) in COVID-19 patients with prior stroke.(25) However 
after matching for demographics and comorbidities these differences were markedly 
reduced with the difference in rate of hospitalisation falling to 32.3% versus 26.0%, 
and the death rate not being significantly elevated (13.4% versus 12.9%). This 
suggests that much of the increased risk of severe COVID-19 infection associated with 
a past history of stroke is explained by comorbidities including vascular risk factors 
such as hypertension, diabetes, and obesity which are known to increase the risk of 
severe COVID, and disability resulting from the stroke. The consequences of COVID-
19 infection have been reported to be particularly severe in individuals with dementia, 
whether this results from a neurodegenerative or vascular cause.(26)  
 
A number of stroke patients ask whether it is safe to take the COVID vaccine. There 
is no evidence of any specific risk in stroke patients, and public health bodies are 




Stroke is already an unequal disease. Sociodemographic factors are an important risk 
factor for stroke and there are widespread geographical disparities in stroke incidence 
and outcome. While stroke incidence appears to be reducing in many higher income 
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countries, in many Low and Middle Income Countries it is increasing.(27) These 
striking inequalities have been exacerbated by COVID-19. Socioeconomic status, 
education, and ethnicity are risk factors for mortality secondary to COVID.(28) 
Preventable conditions including cardiovascular disease and type 2 diabetes are 
themselves major risk factors for dying from COVID-19 (29) and these 
disproportionally effect people living in disadvantaged areas and from ethnic minority 
backgrounds. A survey of stroke survivors in Brazil during the pandemic found 59% 
were in financial difficulties, 48% had difficulties getting food, and 42% had 
appointments with doctors cancelled. (unpublished data, Brazilian Stroke Network 
Survey).  
 
The pandemic has emphasised the deep inequalities and differences in life 
expectancy that exist between different groups within individual countries, and 
between countries. There is a danger that the economic consequences of the 
pandemic will further exacerbate global inequalities. Only National governmental and 
International initiatives can address these issues.  
 
 
Impact of the pandemic on stroke research  
 
The pandemic has had a major impact on stroke research. Initially most stroke journals 
saw an unexpected increase in submission. The International Journal of Stroke, the 
WSO flagship journal, received 58% more submissions from April to June 2020 
compared with the previous 4 months.(Fig 1) This presumably reflected  ‘catch-up’ 
writing during the lockdown. However the long term consequences have been more 
worrying. Charitable research income has been badly hit resulting in many schemes 
funding stroke research being temporarily halted. As an example, the Association of 
Medical Research Charities (AMRC) in the UK’s research sector, which invested £1.9 
billion in medical research in 2019, had a 38% loss in fundraising income.(30) Seventy 
percent of all UK clinical trials and studies were paused in April 2020 and 54% 
remained paused in June.(30) The impact on charitable research funding is likely to 
remain for some time, and countries will be dependent on governmental funding being 
maintained, or even increased, to make up this shortfall. The long-term economic 
consequences of the pandemic may also reduce governmental funding.  
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The long period of lockdown and restricted working during the pandemic has had a 
major impact on young researchers, which has been particularly severe for female 
researchers with childcare responsibilities.(31) There has been much discussion as to 
how funding and other bodies can mitigate these consequences. There has been a 
proliferation of research papers on COVID-19, and a corresponding exponential 
increase in papers examining its association with stroke. Many of these have been of 
poor quality and the expedited review processes implemented have sometimes been 
less rigorous. There have been a large number of papers retractions and articles have 
highlighted the ‘carnage of substandard research’ related to COVID-19.(32) However 
conversely the pandemic has led to a sharing of expertise and impressive 
collaboration and streamlining of processes for clinical trials. For example the 
RECOVERY series of trials that may be beneficial in patients with COVID-19 have 
recruited over 35 000 participants.(33) In Brazil a research network for COVID-19 was 
created (COALITION) including 92 hospitals, resulting in rapid evaluation of 
treatments including the perspective of a middle income country highly affected by the 
disease.(34) These collaborative ventures have led to rapid assessment of the 
benefits, or lack of benefits of a number of agents. Similarly progress in developing, 
evaluating and regulatory approval for COVID vaccines has been impressive.  
 
Telemedicine in clinical stroke care and research- a possible benefit of the pandemic  
 
Perhaps the biggest benefit for stroke care may be the recognition of the benefits of 
telemedicine. While telemedicine was already widely used for acute stroke 
assessment, particularly in geographically dispersed areas, the pandemic has 
expanded this use. It has highlighted its potential in diverse aspects of stroke care, 
many of which may be beneficial after the pandemic. It also revealed how unprepared 
many health services were for its delivery both in terms of equipment and technical 
familiarity of healthcare professionals.(19) During the pandemic successful application 
has been described in TIA clinics (35), physical, occupational, and speech therapy 
rehabilitation(36), and nursing communication with families.(37)  The benefits of video 
technology, allowing limited examination and an awareness of the patient’s 
expression, over telephone consultation have been demonstrated.(38) It was often 
suggested that many stroke patients, being elderly, would not manage well with the 
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technology but video technology has been shown to be well adopted to by outpatients 
with stroke and cognitive impairment.(38) Even in non-pandemic times this technology 
offers major advantages to patients who can have their consultations while at work or 
in their own home, and avoid often lengthy travel times. The potential of telemedicine 
in performing assessments in clinical trials has also been appreciated(39). Perhaps 
these advances are something we can take forward into the future.  
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